Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Alnylam Pharmaceuticals is conducting an observational study titled ‘NeuroFeeL Study’ to evaluate Neurofilament Light Chain (NfL) as a biomarker in asymptomatic carriers of Transthyretin (TTR) variants and patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. The study aims to assess NfL’s potential in diagnosing, detecting disease onset, monitoring progression, and treatment response, highlighting its significance in improving patient outcomes.
Intervention/Treatment: The study involves no direct intervention or treatment administration. Instead, it observes participants under the ‘Standard of Care,’ where medical data and blood samples are collected during routine visits to analyze NfL levels.
Study Design: This is a prospective, cohort-based observational study. It includes a cross-sectional part for a single NfL measurement and a longitudinal part for ongoing NfL level assessments over time, focusing on both asymptomatic carriers and symptomatic patients.
Study Timeline: The study began on April 25, 2024, with primary completion anticipated in the future. The latest update was submitted on June 24, 2025, indicating ongoing recruitment and data collection efforts.
Market Implications: This study could influence Alnylam Pharmaceuticals’ stock performance by potentially validating NfL as a critical biomarker, enhancing treatment strategies for hATTR amyloidosis. Positive outcomes may boost investor confidence and position Alnylam favorably against competitors in the amyloidosis treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.